No Data
No Data
William Blair Maintains Kezar Life Sciences(KZR.US) With Hold Rating
Express News | Kezar Life Sciences to Present at Virtual Kol Event Hosted by William Blair on Zetomipzomib Clinical Development in Autoimmune Hepatitis and Provide a Safety Update From the Palizade Trial for Lupus Nephritis on February 27, 2025
Express News | Kezar Life Sciences, Inc. Files for Mixed Shelf of Upto $400 Mln
Wells Fargo Maintains Kezar Life Sciences(KZR.US) With Hold Rating, Cuts Target Price to $9
Express News | Kezar Life Sciences Inc - Enters Into Amendment No. 1 to Rights Agreement
H.C. Wainwright Maintains Kezar Life Sciences(KZR.US) With Hold Rating